MAP2K7 and melanoma: Furthermore, the results of combined immune checkpoint and kinase inhibitor therapy was recently summarized,45 and a triple therapy consisting of atezolizumab, the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib was approved as first‐line treatment in BRAFV600 melanoma patients.